The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zhabina O.A.

Research Institute of Eye Diseases, 11 A,B Rossolimo St., Moscow, Russian Federation, 119021

Woods E.A.

Research Institute of Eye Diseases, 11 A, B, Rossolimo St., Moscow, Russian Federation, 119021

Pliukhova A.A.

FGBU "NII glaznykh bolezneĭ" RAMN, Moskva

Modern views on myopic maculopathy

Authors:

Zhabina O.A., Woods E.A., Pliukhova A.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2016;132(1): 85‑90

DOI: 10.17116/oftalma2016132185-90

Views: 2453

Downloaded: 76

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Zhabina OA, Woods EA, Pliukhova AA. Modern views on myopic maculopathy. Russian Annals of Ophthalmology. 2016;132(1):85‑90. (In Russ.)
https://doi.org/10.17116/oftalma2016132185-90

Подписка 2025 (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata

Most of world’s scientists consider the fast-growing incidence of myopia a problem of great social importance due to associated increase in complicated myopia that leads to disability among the working-age population. This is a review on complicated myopia and myopic maculopathy that covers the history of research in this field, principles of classification, and etiological factors. It also deals with choroidal neovascularization (CNV), which often follows, and its treatment options, including anti-VEGF therapy. Possible complications of the latter are described as well. Literature search was done using PubMed, eLIBRARY, and Scopus text databases. A total of 61 sources, both Russian and foreign, were analyzed. Current clinical knowledge of different types of myopic maculopathy is still insufficient and the gaps are likely to be filled using modern methods of detailed in vivo examination of both sclera and choroidea. Anti-VEGF therapy has proved most effective in treating myopic maculopathy-associated neovascularization, however, a systematic approach to patient selection and management is yet needed.

Keywords:

myopia
myopic maculopathy
subretinal neovascular membrane
anti-VEGF therapy
choroidal neovascularization
ranibizumab
intraocular pressure

Authors:

Zhabina O.A.

Research Institute of Eye Diseases, 11 A,B Rossolimo St., Moscow, Russian Federation, 119021

Woods E.A.

Research Institute of Eye Diseases, 11 A, B, Rossolimo St., Moscow, Russian Federation, 119021

Pliukhova A.A.

FGBU "NII glaznykh bolezneĭ" RAMN, Moskva

List of references:

  1. Vitale S, Sperduto RD, Ferris FL. Increased prevalence of myopia in the United States between 1971—1972 and 1999—2004. Arch Ophthalmol. 2009;127(12):1632-1639. doi:10.1001/archophthalmol.2009.303.
  2. Lin LL, Shih YF, Tsai CB, Chen CJ, Lee LA, Hung PT. Epidemiologic study of ocular refraction among schoolchildren in Taiwan in 1995. Optom Vis Sci. 1999;76:275-281. doi:10.1097/00006324-199905000-0001.
  3. Saw SM, Katz J, Schein OD, Chew SJ, Chan TK. Epidemiology of myopia. Epidemiol Rev. 1996;18:175-187.  doi:10.1093/oxfordjournals.epirev.a017924.
  4. Sperduto RD, Seigel D, Roberts J, Rowland M. Prevalence of myopia in the United States. Arch Ophthalmol. 1983;101(3):405-407.  doi:10.1001/archopht.1983.01040010405011.
  5. Curtin BJ, Karlin DB. Axial length measurements and fundus changes of the myopic eye. Am J Ophthalmol. 1971;71(1,Pt 1):42-53.  doi:10.1016/0002-9394(71)91092-0.
  6. Xiang F, He M, Zeng Y, Mai J, Rose KA, Morgan IG. Increases in the prevalence of reduced visual acuity and myopia in Chinese children in Guangzhou over the past 20 years. Eye (Lond). 2013;27(12):1353-1358. doi:10.1038/eye.2013.194.
  7. Javitt JC, Chiang YP. The socioeconomic aspects of laser refractive surgery. Arch Opthalmol. 1994;112(12):1526-1530. doi:10.1001/archopht.1994.01090240032022.
  8. Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ. 2008;86(1):63-70.  doi:10.2471/blt.07.041210.
  9. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003;110(7):1297-1305. doi:10.1016/s0161-6420(03)00461-5.
  10. Libman E.S. Slepota i invalidnost' vsledstvie patologii organa zreniya v Rossii. V kn.: Avetisov S.E., Egorov E.A., Moshetova L.K., Neroev V.V., red. Oftal'momlogiya. Natsional'noe rukovodstvo. M.: GEOTAR-Media; 2008:19-31.
  11. Avetisov S.E. Sovremennye aspekty korrektsii refraktsionnykh narushenii. Vestnik oftal'mologii. 2004;120(1):19.
  12. Avetisov E.S. Blizorukost'. M.: Meditsina; 2009.
  13. Borodina N.V., Karapetyan A.T. Anatomo-funktsional'nye pokazateli glaza i razvitie miopii. Vestnik oftal'mologii. 2012;128(6):65-65.
  14. Cheng CY, Schache M, Ikram MK, Young TL, Guggenheim JA, Vitart V, MacGregor S, Verhoeven VJ, Barathi VA, Liao J, Hysi PG, Bailey-Wilson JE et al. Nine loci for ocular axial length identified through genome-wide association studies, including shared loci with refractive error. Am J Hum Genet. 2013;93(2):264-277.  doi:10.1016/j.ajhg.2013.06.016.
  15. Verhoeven VJ, Hysi PG, Wojciechowski R, Fan Q, Guggenheim JA, Höhn R, MacGregor S, Hewitt AW, Nag A, Cheng CY, Yonova-Doing E et al. Genome-wide meta-analyses of multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. Nat Genet. 2013;45(3):314-318. doi:10.1038/ng0613-712b.
  16. Miyake M, Yamashiro K. Heritability Estimation of Axial Length and Refractive Error Explained by Genome-Wide Single Nucleotide Polymorphisms. ARVO 2013, Final ID: 1734, May 2013, Seattle, WA, USA.
  17. Rose KA, Morgan IG, Ip J, Kifley A, Hunyh S, Smith W, Mitchell P. Outdoor activity reduces the prevalence of myopia in children. Opthalmology. 2008;115(8):1279-1285. doi:10.1016/j.ophtha.2007.12.019.
  18. Jones LA, Sinnott LT, Mutti DO, Mitchell GL, Moeschberger ML, Zadnik K. Parental history of myopia, sports and outdoor activities and future myopia. Invest Opthalmol Vis Sci. 2007;48(8):3524-3532. doi:10.1167/iovs.06-1118.
  19. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina. 1992;12(2):127-133.  doi:10.1097/00006982-199212020-00009.
  20. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology. 1984;91(12):1573-1581. doi:10.1016/s0161-6420(84)34116-1.
  21. Tokoro T. Types of fundus changes in the posterior pole. In: Tokoro T, ed. Atlas of posterior fundus changes in pathologic myopia. Tokyo: Springer-Verlag; 1998:5-22. doi:10.1007/978-4-431-67951-6_3.
  22. Klein RM, Curtin BJ. Lacquer crack lesions in pathologic myopia. Am J Ophthalmol. 1975;79(3):386-392.  doi:10.1016/0002-9394(75)90611-x.
  23. Ohno-Matsui K, Tokoro T. The progression of lacquer cracks in pathologic myopia. Retina 1996;16(1):29-37.  doi:10.1097/00006982-199616010-00006.
  24. Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Kojima A, Hayashi W, Yasuzumi K, Nagaoka N, Saka N, Yoshida T, Tokoro T, Mochizuki M. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmolog. 2010;117(8):1595-1611. doi:10.1016/j.ophtha.2009.11.003.
  25. Ohno-Matsui K. Complicated mechanism for axial elongation in eyes with pathologic myopia accompanying scleral thinning and deformity. Graefes Arch Clin Exp Ophthalmol. 2013;251(9):2279. doi:10.1007/s00417-013-2278-7.
  26. Schargus M, Pauleikoff D, Haeusser-Fruh G, Maier MM. Choroidal neovascularisation in pathological myopia: epidemiological data from a health services research study conducted in Germany. Klin Monbl Augenheilkd. 2013;230(7):707-714.  doi:10.1055/s-0032-1328254.
  27. Avetisov S.E., Budzinskaya M.V., Likhvantseva V.G. Fotodinamicheskaya terapiya: perspektivy primeneniya v oftal'mologii. Vestnik oftal'mologii. 2005;121(5):3-6.
  28. Avetisov S.E., Budzinskaya M.V., Likhvantseva V.G., Gurova I.V., Loshchenov V.B., Shevchik S.A., Kuz'min S.G., Vorozhtsov G.N. Pervye rezul'taty IIa fazy klinicheskikh issledovanii fotodinamicheskoi terapii s preparatom «Fotosens» subretinal'nykh neovaskulyarnykh membran. Vestnik oftal'mologii. 2005;121(5):6-9.
  29. Budzinskaya M.V., Vorozhtsov G.N., Ermakova N.A., Kuz'min S.G., Loshchenov V.B., Loshchenov M.V., Luk'yanets E.A., Luzhkov Yu.M., Meerovich G.A., Shevchik S.A. Ustroistvo i sposob diagnostiki i fotodinamicheskoi terapii zabolevanii glaz. Patent na izobretenie RF №2258452 ot 03.09.2003.
  30. Secretan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997;7(4);307-316.
  31. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularizationsecondary to pathological myopia: A pilot study. Br J Ophthalmol. 2007;91(2):174-179. doi:10.1136/bjo.2006.103606.
  32. Krebs I, Binder S, Stolba U, Glittenberg C, Brannath W, Goll A. Choroidal neovascularizationin Pathologic Myopia: Three-year results after PDT. Am J Ophthalmol. 2005;140(3):416-425.  doi:10.1016/j.ajo.2005.03.050.
  33. Avetisov S.E., Budzinskaya M.V., Kiseleva T.N., Kazaryan E.E., Gurova I.V., Smirnova T.V., Shchegoleva I.V., Privivkova E.A., Loshchenov V.B., Shevchik S.A., Kuz'min S.G., Vorozhtsov G.N. Fotodinamicheskaya terapiya subretinal'nykh neovaskulyarnykh membran. Soobshchenie 2. Rezul'taty lecheniya oslozhnennoi miopii. Vestnik oftal'mologii. 2007;123(6):8-11.
  34. Klais CM, Ober MD, Freund KB, Ginsburg LH, Luckie A, Mauget-Faÿsse M, Coscas G, Gross NE, Yannuzzi LA. Choroidal infarction following photodynamic therapy with verteporfin. Arch. Ophthalmol. 2005;123(8)1149-1153. doi:10.1001/archopht.123.8.1149.
  35. Farinha CL, Baltar AS, Nunes SG, Franqueira NF, Figueira JP, Pires IA, Cachulo ML, Silva RM. Choroidal thickness after treatment for myopic choroidal neovascularization. Eur J Ophthalmol. 2013;121(1):220-224. doi:10.5301/ejo.5000323.
  36. Potter MJ, Szabo SM, Ho T. Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year-old girl. Graefe’s Arch. Clin. Exp. Ophthalmol. 2006;244(5);639-641.  doi:10.1007/s00417-005-0115-3.
  37. Degenring RF, Jonas JB. Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization. Acta Ophthalmol. Scand. 2005;83(5):621.  doi:10.1111/j.1600-0420.2005.00506.x.
  38. Miki A, Honda S, Nagai T, Tsukahara Y, Negi A. Effects of oral bisphosphonates on myopic choroidal neovascularisation over 2 years of follow-up: comparison with anti-VEGF therapy and photodynamic therapy. A pilot study. Br. J. Ophthalmol. 2013;97(6):770-774.  doi:10.1136/bjophthalmol-2012-303007.
  39. Ohji M, Fujikado T, Kusaka S, Hayashi A, Hosohata J, Ikuno Y, Sawa M, Kubota A, Hashida N, Tano Y. Comparison of three techniques of foveal translocation in patients with subfoveal choroidal neovascularization resulting from age-related macular degeneration. Am. J. Ophthalmol. 2001;132(6):888-896.  doi:10.1016/s0002-9394(01)01255-7.
  40. Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br. J. Ophthalmol. 2001;85(9):1041-1043. doi:10.1136/bjo.85.9.1041.
  41. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE,Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. The New England Journal of Medicine. 1994;331(22):1480-1487. doi:10.1056/nejm199412013312203.
  42. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105(2):232-237. doi:10.1016/s0161-6420(98)92782-8.
  43. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Archives of Ophthalmology. 2007;125(10):1363-1366. doi:10.1001/archopht.125.10.1363.
  44. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Archives of Ophthalmology. 1996;114(8):964-970.  doi:10.1001/archopht.1996.01100140172010.
  45. Wakabayashi T, Ikuno Y, Oshima Y, Hamasaki T, Nishida K. Aqueous Concentrations of Vascular Endothelial Growth Factor in Eyes with High Myopia with and without Choroidal Neovascularization. J. Ophthalmol. 2013;2013:257381. doi:10.1155/2013/257381.
  46. Lai TY, Luk FO, Lee GK, Lam DS. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond). 2012;26(7):1004-1011. doi:10.1038/eye.2012.97.
  47. Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004;351(27):2805-2816. doi:10.1056/nejmoa042760.
  48. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26(3):262-269.  doi:10.1097/00006982-200603000-00002.
  49. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chévez-Barrios P. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26(3):257-261. doi:10.1097/00006982-200603000-00001.
  50. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia . Br. J. Ophthalmol. 2007;91(2):157-160.  doi:10.1136/bjo.2006.096776.
  51. Hefner. L, Riese. J, Gerding. H. Three years follow-up results of ranibizumab treatment for choroidal neovascularization secondary to pathologic myopia. Klin. Monbl. Augenheilkd. 2013;230(4):401-404. doi:10.1055/s-0032-1328366.
  52. Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Osoba O, Gale R, George S, Lotery AJ, Majid M, McKibbin M, Menon G, Andrews C, Brittain C, Osborne A, Yang Y. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120(9):1944-1945. doi:10.1016/j.ophtha.2013.06.010.
  53. Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological-myopia: 4-year outcome. Br. J. Ophthalmol. 2013;97(11):1447-1450. doi:10.1136/bjophthalmol-2012-302973.
  54. Miyake M, Yamashiro K, Akagi-Kurashige Y, Kumagai K, Nakata I, Nakanishi H, Oishi A, Tsujikawa A, Yamada R, Matsuda F, Yoshimura N. Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia. Ophthalmology. 2014;121(1):225-233.  doi:10.1016/j.ophtha.2013.06.043.
  55. Avetisov S.E., Budzinskaya M.V., Kazaryan E.E., Gurova I.V. Diagnosticheskoe znachenie prizhiznennoi morfometrii setchatki u patsientov s subretinal'noi neovaskulyarizatsiei. Vestnik oftal'mologii. 2007;123(1):3-7.
  56. Lai TY, Luk FO, Lee GK, Lam DS. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond). 2012;26(7):1004-1011. doi:10.1038/eye.2012.97.
  57. Gutfleisch M, Heimes B, Schumacher M, Dietzel M, Lommatzsch A, Bird A, Pauleikhoff D. Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD. Eye (Lond). 2011;25(9):1181-1186. doi:10.1038/eye.2011.146.
  58. Jonas JB, Schmidbauer M, Rensch F. Progression of tractional retinal detachment following intravitreal bevacizumab. Acta Ophthalmol. 2009;87(5):571-572.  doi:10.1111/j.1755-3768.2008.01225.x.
  59. Mamikonyan V.R., Galoyan N.S., Budzinskaya M.V., Kazaryan E.E., Sdobnikova S.V., Shmeleva-Demir O.A., Rafaelyan A.A. Osobennosti vnutriglaznogo davleniya i glaznogo krovotoka pri intravitreal'nom vvedenii preparatov, ingibiruyushchikh faktor rosta sosudistogo endoteliya. Vestnik oftal'mologii. 2014;130(5):16-21.
  60. Avetisov S.E., Erichev V.P., Budzinskaya M.V., Karpilova M.A. Vozrastnaya makulyarnaya degeneratsiya i vnutriglaznaya gipertenziya. Natsional'nyi zhurnal glaukoma. 2013;1:62-67.
  61. Avetisov S.E., Erichev V.P., Budzinskaya M.V., Karpilova M.A., Shchegoleva I.V., Gurova I.V., Chikun E.A. Vozrastnaya makulyarnaya degeneratsiya i glaukoma: monitoring vnutriglaznogo davleniya posle intravitreal'nykh in''ektsii. Vestnik oftal'mologii. 2012;128(6):3-5.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.